National Institutes of Health StrokeNet during the Time of COVID-19 and beyond

Joseph P. Broderick; Jordan J. Elm; L. Scott Janis; Wenle Zhao; Claudia S. Moy; Catherine R. Dillon; Marc I. Chimowitz; Ralph L. Sacco; Steven C. Cramer; Steven L. Wolf; Karen C. Johnston; Jeffrey L. Saver; Randolph S. Marshall; Devin Brown; Max Wintermark; Mitchell S.V. Elkind; Hooman Kamel; David L. Tirschwell; W. T. Longstreth; Ronald D. Chervin; Opeolu M. Adeoye; Andrew D. Barreto; James C. Grotta; Sharon L. Ramey; Warren D. Lo; Wuwei Feng; Gottfried Schlaug; Kevin N. Sheth; Magdy Selim; Andrew M. Naidech; Maarten G. Lansberg; Ronald M. Lazar; Gregory W. Albers; Jessica S. Griffin; Logan P. Sirline; Jamey Frasure; Clinton B. Wright; Pooja Khatri

doi:10.1161/STROKEAHA.120.030417

National Institutes of Health StrokeNet during the Time of COVID-19 and beyond

Joseph P. Broderick, Jordan J. Elm, L. Scott Janis, Wenle Zhao, Claudia S. Moy, Catherine R. Dillon, Marc I. Chimowitz, Ralph L. Sacco, Steven C. Cramer, Steven L. Wolf, Karen C. Johnston, Jeffrey L. Saver, Randolph S. Marshall, Devin Brown, Max Wintermark, Mitchell S.V. Elkind, Hooman Kamel, David L. Tirschwell, W. T. Longstreth, Ronald D. ChervinOpeolu M. Adeoye, Andrew D. Barreto, James C. Grotta, Sharon L. Ramey, Warren D. Lo, Wuwei Feng, Gottfried Schlaug, Kevin N. Sheth, Magdy Selim, Andrew M. Naidech, Maarten G. Lansberg, Ronald M. Lazar, Gregory W. Albers, Jessica S. Griffin, Logan P. Sirline, Jamey Frasure, Clinton B. Wright, Pooja Khatri

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Original language	English
Pages (from-to)	2580-2586
Number of pages	7
Journal	Stroke
Volume	51
Issue number	8
DOIs	https://doi.org/10.1161/STROKEAHA.120.030417
State	Published - Aug 1 2020

Keywords

United States
biomarkers
data management
therapeutics

Access to Document

10.1161/STROKEAHA.120.030417

Cite this

Broderick, J. P., Elm, J. J., Janis, L. S., Zhao, W., Moy, C. S., Dillon, C. R., Chimowitz, M. I., Sacco, R. L., Cramer, S. C., Wolf, S. L., Johnston, K. C., Saver, J. L., Marshall, R. S., Brown, D., Wintermark, M., Elkind, M. S. V., Kamel, H., Tirschwell, D. L., Longstreth, W. T., ... Khatri, P. (2020). National Institutes of Health StrokeNet during the Time of COVID-19 and beyond. Stroke, 51(8), 2580-2586. https://doi.org/10.1161/STROKEAHA.120.030417

@article{836199a4ca1e415eba77dcf67960bdeb,

title = "National Institutes of Health StrokeNet during the Time of COVID-19 and beyond",

keywords = "United States, biomarkers, data management, therapeutics",

author = "Broderick, {Joseph P.} and Elm, {Jordan J.} and Janis, {L. Scott} and Wenle Zhao and Moy, {Claudia S.} and Dillon, {Catherine R.} and Chimowitz, {Marc I.} and Sacco, {Ralph L.} and Cramer, {Steven C.} and Wolf, {Steven L.} and Johnston, {Karen C.} and Saver, {Jeffrey L.} and Marshall, {Randolph S.} and Devin Brown and Max Wintermark and Elkind, {Mitchell S.V.} and Hooman Kamel and Tirschwell, {David L.} and Longstreth, {W. T.} and Chervin, {Ronald D.} and Adeoye, {Opeolu M.} and Barreto, {Andrew D.} and Grotta, {James C.} and Ramey, {Sharon L.} and Lo, {Warren D.} and Wuwei Feng and Gottfried Schlaug and Sheth, {Kevin N.} and Magdy Selim and Naidech, {Andrew M.} and Lansberg, {Maarten G.} and Lazar, {Ronald M.} and Albers, {Gregory W.} and Griffin, {Jessica S.} and Sirline, {Logan P.} and Jamey Frasure and Wright, {Clinton B.} and Pooja Khatri",

note = "Funding Information: tween 4.5 and 24 Hours) and from Ono Pharmaceuticals for role as consultant. Dr Wolf serves on the Scientific Advisory Board of SAEBO, Inc, and is a paid consultant to Motus Nova, Inc. Dr Kamel is a co-PI for the NIH-funded ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke) that receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics, deputy editor for JAMA Neurology, Steering Committee member of Medtronic Stroke AF trial (uncompensated), end point adjudication committee for a trial of empagliflozin for Boehringer Ingel-heim, and advisory board for Roivant Sciences related to Factor XI inhibition. Dr Elkind is a co-PI for the NIH-funded ARCADIA trial that receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics and reports royalties from UpToDate for chapter on cryptogenic stroke. Dr Tirschwell is a co-PI for the NIH-funded ARCADIA trial (NINDS [National Institute of Neurological Disorders and Stroke] U01 NS095869) that receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics. Dr Longstreth is a co-PI for the NIH-funded ARCADIA trial that receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics. Dr Cramer is a consultant for Abbvie, Constant Therapeutics, MicroTransponder, Neurolutions, Regenera, SanBio, Stemedica, Fujifilm Toyama Chemical, Co, Biogen, and TRCare. Dr Sacco reports research grants from NIH and FL Department of Health; institutional support from Boehringer Ingelheim for role on executive committee of RE-SPECT ESUS trial (Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source); and personal fees, Editor-in-Chief, Stroke. Dr Johnston reports research grants from NIH and Virginia Catalyst, consulting for Food and Drug Administration, member of NIH-NINDS council, grant funding and consulting for Diffusion Pharmaceutical, and Data Safety Monitoring Boards for Biogen and Rivanna Medical–joint research program. Dr Albers reports equity and consulting for iSchemaView and consulting for Genentech. Dr Adeoye is a cofounder and equity holder for Sense Diagnostics, Inc, and belongs to the Scientific Advisory Board for Acticor. Dr Barreto reports nonfinancial support from Glaxo-Smith-Kline, Inc, and Mitsubishi Pharma EU and consulting fees from Cerevast Therapeutics, Inc, and Genentech, Inc. Dr Grotta is a PI of Patient-Centered Outcomes Research Institute-funded BEST-MSU study (Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit) that receives study medication from Genentech and CSL Behring; co-PI of NIH-funded MOST trial (Multi-Arm Optimization of Stroke Thrombolysis) and FASTEST trial, the latter which receives study medication from Novo Nordisk; Scientific Advisory Board for Haemonetics and Acticor; and consultant for Frazer, Ltd. Dr Chervin reports research grants from NIH; he has served as a consultant for Zansors and editor and author for UpToDate; he has produced copyrighted material, patents, and patents pending, owned by the University of Michigan, focused on assessment or treatment of sleep disorders; he has served on the Boards of Directors for the American Academy of Sleep Medicine, Associated Professional Sleep Societies, International Pediatric Sleep Association, and the nonprofit Sweet Dreamzzz and on an advisory board for the nonprofit Pajama Program; and reports personal fees from Cambridge Press for role as editor. Dr Schlaug reports research grants from NIH and is an associate editor for Annals of Neurology. Dr Lansberg is a consultant for Biogen, Genentech, NuvOx Pharma, and Nektar Therapeutics. Dr Sheth reports research grants from NIH and the American Heart Association, Hyerfine, Novartis, Biogen, and Bard; is a consultant for Zoll; and reports equity in Alva. Dr Khatri reports funds from Cerenovus (Investigator Initiated Study grant multiple principal investigator), Nervive (NINDS grant coinvestigator), Bayer (Trial National PI), Lumosa (consultant), Diamedica (Scientific Advisory Board), and UpToDate (royalties). The other authors report no conflicts.",

year = "2020",

month = aug,

day = "1",

doi = "10.1161/STROKEAHA.120.030417",

language = "English",

volume = "51",

pages = "2580--2586",

journal = "Stroke",

issn = "0039-2499",

number = "8",

}

Broderick, JP, Elm, JJ, Janis, LS, Zhao, W, Moy, CS, Dillon, CR, Chimowitz, MI, Sacco, RL, Cramer, SC, Wolf, SL, Johnston, KC, Saver, JL, Marshall, RS, Brown, D, Wintermark, M, Elkind, MSV, Kamel, H, Tirschwell, DL, Longstreth, WT, Chervin, RD, Adeoye, OM, Barreto, AD, Grotta, JC, Ramey, SL, Lo, WD, Feng, W, Schlaug, G, Sheth, KN, Selim, M, Naidech, AM, Lansberg, MG, Lazar, RM, Albers, GW, Griffin, JS, Sirline, LP, Frasure, J, Wright, CB & Khatri, P 2020, 'National Institutes of Health StrokeNet during the Time of COVID-19 and beyond', Stroke, vol. 51, no. 8, pp. 2580-2586. https://doi.org/10.1161/STROKEAHA.120.030417

TY - JOUR

T1 - National Institutes of Health StrokeNet during the Time of COVID-19 and beyond

AU - Broderick, Joseph P.

AU - Elm, Jordan J.

AU - Janis, L. Scott

AU - Zhao, Wenle

AU - Moy, Claudia S.

AU - Dillon, Catherine R.

AU - Chimowitz, Marc I.

AU - Sacco, Ralph L.

AU - Cramer, Steven C.

AU - Wolf, Steven L.

AU - Johnston, Karen C.

AU - Saver, Jeffrey L.

AU - Marshall, Randolph S.

AU - Brown, Devin

AU - Wintermark, Max

AU - Elkind, Mitchell S.V.

AU - Kamel, Hooman

AU - Tirschwell, David L.

AU - Longstreth, W. T.

AU - Chervin, Ronald D.

AU - Adeoye, Opeolu M.

AU - Barreto, Andrew D.

AU - Grotta, James C.

AU - Ramey, Sharon L.

AU - Lo, Warren D.

AU - Feng, Wuwei

AU - Schlaug, Gottfried

AU - Sheth, Kevin N.

AU - Selim, Magdy

AU - Naidech, Andrew M.

AU - Lansberg, Maarten G.

AU - Lazar, Ronald M.

AU - Albers, Gregory W.

AU - Griffin, Jessica S.

AU - Sirline, Logan P.

AU - Frasure, Jamey

AU - Wright, Clinton B.

AU - Khatri, Pooja

N1 - Funding Information: tween 4.5 and 24 Hours) and from Ono Pharmaceuticals for role as consultant. Dr Wolf serves on the Scientific Advisory Board of SAEBO, Inc, and is a paid consultant to Motus Nova, Inc. Dr Kamel is a co-PI for the NIH-funded ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke) that receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics, deputy editor for JAMA Neurology, Steering Committee member of Medtronic Stroke AF trial (uncompensated), end point adjudication committee for a trial of empagliflozin for Boehringer Ingel-heim, and advisory board for Roivant Sciences related to Factor XI inhibition. Dr Elkind is a co-PI for the NIH-funded ARCADIA trial that receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics and reports royalties from UpToDate for chapter on cryptogenic stroke. Dr Tirschwell is a co-PI for the NIH-funded ARCADIA trial (NINDS [National Institute of Neurological Disorders and Stroke] U01 NS095869) that receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics. Dr Longstreth is a co-PI for the NIH-funded ARCADIA trial that receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics. Dr Cramer is a consultant for Abbvie, Constant Therapeutics, MicroTransponder, Neurolutions, Regenera, SanBio, Stemedica, Fujifilm Toyama Chemical, Co, Biogen, and TRCare. Dr Sacco reports research grants from NIH and FL Department of Health; institutional support from Boehringer Ingelheim for role on executive committee of RE-SPECT ESUS trial (Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source); and personal fees, Editor-in-Chief, Stroke. Dr Johnston reports research grants from NIH and Virginia Catalyst, consulting for Food and Drug Administration, member of NIH-NINDS council, grant funding and consulting for Diffusion Pharmaceutical, and Data Safety Monitoring Boards for Biogen and Rivanna Medical–joint research program. Dr Albers reports equity and consulting for iSchemaView and consulting for Genentech. Dr Adeoye is a cofounder and equity holder for Sense Diagnostics, Inc, and belongs to the Scientific Advisory Board for Acticor. Dr Barreto reports nonfinancial support from Glaxo-Smith-Kline, Inc, and Mitsubishi Pharma EU and consulting fees from Cerevast Therapeutics, Inc, and Genentech, Inc. Dr Grotta is a PI of Patient-Centered Outcomes Research Institute-funded BEST-MSU study (Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit) that receives study medication from Genentech and CSL Behring; co-PI of NIH-funded MOST trial (Multi-Arm Optimization of Stroke Thrombolysis) and FASTEST trial, the latter which receives study medication from Novo Nordisk; Scientific Advisory Board for Haemonetics and Acticor; and consultant for Frazer, Ltd. Dr Chervin reports research grants from NIH; he has served as a consultant for Zansors and editor and author for UpToDate; he has produced copyrighted material, patents, and patents pending, owned by the University of Michigan, focused on assessment or treatment of sleep disorders; he has served on the Boards of Directors for the American Academy of Sleep Medicine, Associated Professional Sleep Societies, International Pediatric Sleep Association, and the nonprofit Sweet Dreamzzz and on an advisory board for the nonprofit Pajama Program; and reports personal fees from Cambridge Press for role as editor. Dr Schlaug reports research grants from NIH and is an associate editor for Annals of Neurology. Dr Lansberg is a consultant for Biogen, Genentech, NuvOx Pharma, and Nektar Therapeutics. Dr Sheth reports research grants from NIH and the American Heart Association, Hyerfine, Novartis, Biogen, and Bard; is a consultant for Zoll; and reports equity in Alva. Dr Khatri reports funds from Cerenovus (Investigator Initiated Study grant multiple principal investigator), Nervive (NINDS grant coinvestigator), Bayer (Trial National PI), Lumosa (consultant), Diamedica (Scientific Advisory Board), and UpToDate (royalties). The other authors report no conflicts.

PY - 2020/8/1

Y1 - 2020/8/1

KW - United States

KW - biomarkers

KW - data management

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85088799230&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.120.030417

DO - 10.1161/STROKEAHA.120.030417

M3 - Review article

C2 - 32716819

AN - SCOPUS:85088799230

VL - 51

SP - 2580

EP - 2586

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 8

ER -

National Institutes of Health StrokeNet during the Time of COVID-19 and beyond

Keywords

Access to Document

Other files and links

Cite this